


## Investigational Trial of Iberdomide (CC-220) in Patients With Relapsed or Refractory Lymphomas

CC-220-NHL-001

A Phase 1/2, Multicenter, Open-Label Study to Assess Safety,
Pharmacokinetics, and Preliminary Efficacy of Iberdomide (CC-220),
Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas<sup>1</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of iberdomide (CC-220) and/or its uses are under investigation and have not been established.

There is no guarantee that iberdomide (CC-220) will receive health authority approval or become commercially available in any country for the uses being investigated.